The National Cancer Institute has awarded a group of researchers a $3.3 million, five-year grant to produce software to predict therapies for women with ER+ breast cancer. The software recognizes minute features in pathology images and develops an image-based risk score to distinguish between those patients who need chemotherapy and those who need only the more tolerable hormonal therapy. The collaboration between researchers at Case Western Reserve University, Rutgers University, SUNY Buffalo, the University of Pennsylvania, and industry is intended to develop this quick and inexpensive test for women with ER+ breast cancer. Dr. Michael Feldman, Associate Professor of Pathology and Laboratory Medicine and Director of Bioinformatics, is part of the study.
Read the Case Western Reserve University press release.